Corporate calendar for BioAtla, Inc. (BCAB): upcoming earnings dates, dividend ex-dates and payment dates, stock splits, shareholder meetings and conference calls. Plan your positions around the key catalysts.
BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC), and ovarian cancer.
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|---|---|
| 2026-09-14 | ||
| 2026-09-14 | ||
| 2026-09-14 | ||
| 2026-09-14 | ||
| 2026-09-14 | $144M | |
| 2026-09-14 | $898M |
Price
| Price | $1.74 |
| Market Cap | $3M |
| Exchange | NASDAQ |
| Country | US |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 6 |
| Hold | 3 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 9 |
| Avg rating (1-5) | 0.67 |
Related companies: ANVS · BTAI · CELU · EVAX · GBIO · MRSN · MURA
Explore sector: Healthcare · Biotechnology
More sections of BCAB: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · News
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks